 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., March 26, 2024 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of...

Molecular Partners Publishes Invitation to Annual General Meeting 2024

Full Year 2023 Molecular Partners AG Earnings Call Transcript

Molecular Partners AG (MOLN) Q4 2023 Earnings Call Transcript...

Molecular Partners AG (MOLN) Q4 2023 Earnings Call Transcript

Research & Development Highlights Presented encouraging initial data from first four dosing cohorts of ongoing Phase 1/2a trial of MP0533 for patients with relapsed/refractory AML and AML/MDS at the...

Molecular Partners Reports Corporate Highlights From Q4 2023 and Key Financials for Full Year 2023

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., March 01, 2024 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of...

Molecular Partners Announces Dismissal of Class Action Lawsuit

Molecular Partners To Hold Conference Call to Discuss Fourth Quarter and Full Year 2023 Results and Announces Upcoming Investor Presentations

Tetra-specific T-cell engager MP0533 for patients with r/r AML and AML/MDS on track to deliver expanded clinical phase 1/2a data in H1 2024Progress of Radio-DARPin Therapy (RDT) platform: Improved...

Molecular Partners Provides Updates at 42nd Annual J.P. Morgan Healthcare Conference

Collaboration leverages lead-based (212Pb) alpha emitter expertise and supply of Orano Med with Molecular Partners' leadership in DARPins for tumor-targeted delivery of radioactive...

Molecular Partners and Orano Med Announce Co-Development Agreement for Radio-DARPin Therapies

Molecular Partners AG engages in the development of protein therapies for treatment of serious diseases like cancer and sight-threatening disorders. It also develops its products through its brand known as DARPins, which targets specific and potent monoclonal antibodies that offers potential to address existing limitations of antibody drugs. The company products include Abicipar, MP0250/MP0274 and Clinical Trials. The company was founded by Christian Zahnd, Patrick Amstutz, Patrik Forrer, Andreas Plückthun, and Michael Tobias Stumpp on November 22, 2004 and is headquartered in Schlieren, Switzerland.

Volume (M)	5,566.00
52-Wk High	$7.32
52-Wk Low	$3.35

MOLN Molecular Partners AG

About

Feed

News

Earnings

Fundamentals